Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

B-Myb, a repressed trans-activating protein

S Ansieau1, E Kowenz-Leutz, R Dechend

  • 1Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Journal of Molecular Medicine (Berlin, Germany)
|January 15, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of the art approach to managing angina and ischemia: tailoring treatment to the evidence.

European journal of internal medicine·2021
Same author

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.

The British journal of dermatology·2020
Same author

The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?

European journal of internal medicine·2019
Same author

A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.

The British journal of dermatology·2019
Same author

Lymphocyte characterization of decidua basalis spiral arteries with acute atherosis in preeclamptic and normotensive pregnancies.

Journal of reproductive immunology·2019
Same author

[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].

Der Internist·2017
Same journal

Non-transferrin-bound iron uptake by cardiomyocytes.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Beyond the target: implications of Wnt pathway inhibitors on bone health.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Integrative genetic and functional analysis of autosomal dominant hearing loss in 108 multigenerational families.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Zinc-binding protein metallothionein 3 protects vascular smooth muscle cells from ferroptosis via blocking lysosomal degradation of GPX4.

Journal of molecular medicine (Berlin, Germany)·2026
See all related articles

B-Myb transcription factor activity is regulated during the cell cycle. Cyclins A and E activate B-Myb by removing C-terminal inhibition, linking its function to cell cycle progression.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Transcription Factor Research

Background:

  • B-Myb is a transcription factor involved in cell cycle regulation.
  • Its role as an activator or repressor has been debated.
  • Human papillomavirus oncoprotein HPV16 E7 upregulates B-Myb expression.

Purpose of the Study:

  • To investigate the transactivation potential of B-Myb.
  • To identify regulatory mechanisms of B-Myb function in vertebrate cells.
  • To link B-Myb's role to cell cycle progression.

Main Methods:

  • Yeast-based transactivation assays to study B-Myb's potential.
  • Mutational analysis to identify conserved activation domains.
  • Experiments in vertebrate cells to examine regulation by cell cycle proteins.

Related Experiment Videos

Main Results:

  • A conserved activation domain was localized in B-Myb.
  • The C-terminal region of B-Myb inhibits its transactivation potential in vertebrate cells.
  • Cyclin A and cyclin E were found to activate B-Myb by relieving C-terminal inhibition.

Conclusions:

  • B-Myb possesses transactivation potential, regulated by its C-terminus.
  • Cell cycle regulators cyclin A and E modulate B-Myb activity.
  • B-Myb's transactivating function is cell cycle-dependent, connecting it to cell cycle progression.